Eligibility
colonic adenomas, CRC
INFLAMMATORY BOWEL DISEASE, COLORECTAL POLYPS
We used an electronic medical record (EMR) query, augmented by a brief manual chart scrub, to identify all patients who were in the 45–49-year-old age group as of February 2022, had a primary care visit at the FQHC clinic in the prior 18 months (i.e., likely to be active patients per input from the clinic team), were at average risk for CRC, had a North Carolina address, and were not up-to-date on CRC screening. The query and patient eligibility assessment protocols were identical to those used in the larger trial [Patients were excluded from this sub-study if they were known to be at increased risk for CRC due to a personal history of CRC, defined as documented CRC, colorectal polyps, or colonic adenomas; family history of CRC among a first degree relative; or a diagnosis of inflammatory bowel disease. National guidelines do not recommend screening for individuals with limited life expectancy [Consort diagram. *This was an intention-to-treat analysis